Kan Kikuchi
Overview
Explore the profile of Kan Kikuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murakami M, Fujii N, Kanda E, Kikuchi K, Wada A, Hamano T, et al.
Am J Nephrol
. 2024 Sep;
55(6):647-656.
PMID: 39245037
Introduction: The optimal time for vascular access (VA) creation remains controversial. Methods: We conducted a cohort study using data from the Japanese Society for Dialysis Therapy Renal Data Registry. Adult...
2.
Sugawara Y, Iwagami M, Kikuchi K, Hashiba T, Yabushita S, Ryuzaki M, et al.
Nephrology (Carlton)
. 2024 Jul;
29(10):671-679.
PMID: 39023114
Aim: The effectiveness of the coronavirus disease (COVID-19) vaccine in Japanese patients undergoing haemodialysis has previously not been evaluated on a large scale. We analyzed data from the Japanese Society...
3.
Abe M, Kikuchi K, Wada A, Nakai S, Kanda E, Hanafusa N
Sci Rep
. 2024 May;
14(1):10272.
PMID: 38704419
Dialyzers are classified into five types based on their β-microglobulin clearance rate and albumin sieving coefficient: Ia, Ib, IIa, and IIb. In addition, a new classification system introduced a type...
4.
Yoshifuji A, Toda M, Oyama E, Nakayama T, Mise-Omata S, Kikuchi K, et al.
Clin Exp Nephrol
. 2024 Mar;
28(7):674-682.
PMID: 38457030
Background: Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower...
5.
Toyoda H, Kikuchi K
Ther Apher Dial
. 2023 Sep;
28(1):160-161.
PMID: 37771101
No abstract available.
6.
Toda M, Yoshifuji A, Nakayama T, Mise-Omata S, Oyama E, Uwamino Y, et al.
Vaccines (Basel)
. 2023 Jul;
11(7).
PMID: 37515030
Coronavirus disease 2019 (COVID-19) following primary immunization (breakthrough infection) has been reported in hemodialysis patients; however, their post-infection immune status remains unclear. We evaluated the humoral and cellular immunity of...
7.
Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Ota Y, Hanafusa N, et al.
Ther Apher Dial
. 2023 Jul;
27(6):1064-1069.
PMID: 37395555
Introduction: In the present study, the efficacy of sotrovimab and molnupiravir in dialysis patients with COVID-19 was investigated using a registry of COVID-19 in Japanese dialysis patients. Methods: Dialysis patients...
8.
Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy
Toyoda H, Kikuchi K
Ther Apher Dial
. 2023 May;
27(5):831-838.
PMID: 37217295
The clinical use of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection has dramatically changed management of patients with HCV liver disease since 2014; this is also true for...
9.
Yoshifuji A, Toda M, Ryuzaki M, Oyama E, Kikuchi K, Kawai T, et al.
Vaccines (Basel)
. 2023 Mar;
11(3).
PMID: 36992238
Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the...
10.
Murakami M, Fujii N, Kanda E, Kikuchi K, Wada A, Hamano T, et al.
Am J Nephrol
. 2023 Mar;
54(3-4):83-94.
PMID: 36917960
Introduction: Vascular access usage varies widely across countries. Previous studies have evaluated the association of clinical outcomes with the three types of vascular access, namely, arteriovenous fistula (AVF), arteriovenous graft...